CLASSICAL HODGKIN LYMPHOMA
Clinical trials for CLASSICAL HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new CLASSICAL HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for CLASSICAL HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo shows promise for tough-to-treat lymphoma
Disease control OngoingThis study tests whether adding the drug camrelizumab to standard chemotherapy (AVD) helps people with advanced classical Hodgkin lymphoma who have not been treated before. About 60 adults aged 18 to 75 will receive the combination. The main goal is to see how many patients have …
Matched conditions: CLASSICAL HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Henan Cancer Hospital • Aim: Disease control
Last updated Jun 15, 2026 19:05 UTC
-
New tailored therapy offers hope for older hodgkin lymphoma patients
Disease control OngoingThis study tests a treatment plan that adjusts chemotherapy based on a patient's fitness level for adults aged 60 and older with untreated classical Hodgkin lymphoma. All participants receive the immunotherapy drug pembrolizumab plus another targeted drug, then a PET scan and fit…
Matched conditions: CLASSICAL HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: University of Virginia • Aim: Disease control
Last updated Jun 15, 2026 19:04 UTC
-
New drug combo shows promise for Tough-to-Treat hodgkin lymphoma
Disease control OngoingThis study tests whether combining ibrutinib and nivolumab can help people with classical Hodgkin lymphoma that has returned or not responded to prior treatment. About 18 adults will receive both drugs to see if the cancer shrinks or disappears. The goal is to improve disease con…
Matched conditions: CLASSICAL HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 15, 2026 19:02 UTC